Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

6 Jun 2016

Abstract excerpt

Prostate cancer has the second highest incidence among cancers in men worldwide and is the second leading cause of cancer deaths of men in the United States. Although androgen deprivation can initially lead to remission, the disease often progresses to castration-resistant prostate cancer (CRPC), which is still reliant on androgen receptor (AR) signaling and is associated with a poor prognosis. Some success...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27274052
DOI: 10.1073/pnas.1521738113

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancerPMID 27274052Read ↗

PROTACs in the Management of Prostate Cancer.Semantic proximity Read ↗

Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancerSemantic proximity Read ↗

Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancerSemantic proximity Read ↗

Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatmentSemantic proximity Read ↗

Targeting the Undruggable: Recent Progress in PROTAC-Induced Transcription Factor DegradationSemantic proximity Read ↗

BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinationsSemantic proximity Read ↗

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancerSemantic proximity Read ↗

PROTACing the androgen receptor and other emerging therapeutics in prostate cancer.Semantic proximity Read ↗

Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)Semantic proximity Read ↗

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancerSemantic proximity Read ↗

Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate CancerSemantic proximity Read ↗

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.